Business
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
LONDON, February 25, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV.1 Results show a single-dose injection could maintain drug levels for up to six months. In-vitro data from a separate study demonstrate improved potency and an enhanced resistance
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":320,"height":296,"url":"https://media.zenfs.com/en/business-wire.com/90e57c07ca5adffcb25efab7f943b080"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1wrSzVfT4TK2ijDU1AkgPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTU5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/90e57c07ca5adffcb25efab7f943b080","width":320,"height":296}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals","length":125,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegravir","length":116,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"VH499 demonstrates good tolerability, supporting twice-yearly dosing intervals","length":78,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":319,"olType":false},{"type":"text","content":"LONDON, February 25, 2026--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data from its phase 1 study of long-acting formulations of VH184, the first, third-generation integrase strand transfer inhibitor (INSTI) in development for HIV.1 Results show a single-dose injection could maintain drug levels for up to six months. In-vitro data from a separate study demonstrate improved potency and an enhanced resistance profile versus bictegravir in resistant HIV strains.2","length":571,"tagName":"p"},{"type":"text","content":"Additional data from ViiV Healthcare’s long-acting pipeline presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado, show VH499, an investigational capsid inhibitor, was generally well tolerated and support the potential for ultra long-acting (ULA) twice-yearly dosing.3 These early-stage findings, alongside continued progress of other ULA pipeline assets, including lotivibart (N6LS), reinforce ViiV Healthcare’s commitment to advancing innovative long-acting HIV therapies that reduce the need for daily treatment and expand options for...